History | Cemiplimab for treating advanced cutaneous squamous cell carcinoma | Guidance | NICE

History

Documents created during the development process.

Expected publication

Equality Impact Assessment (Guidance development) (PDF 140 KB)

Published:

29 June 2022
Register of interests (PDF 138 KB)

Published:

29 June 2022

Final draft guidance: 1

Final draft guidance: 1
Final appraisal document (PDF 210 KB)

Published:

25 May 2022
Committee papers (PDF 5.44 MB)

Published:

25 May 2022
Public committee slides (PDF 644 KB)

Published:

25 May 2022

Invitation to participate

Final scope (PDF 199 KB)

Published:

03 December 2021
Final stakeholder list (PDF 190 KB)

Published:

03 December 2021

Final draft guidance: TA592

Final appraisal document - TA592 (PDF 257 KB)

Published:

02 July 2019
Committee papers - TA592 (PDF 8.15 MB)

Published:

02 July 2019
Public committee slides - TA592 (PDF 211 KB)

Published:

02 July 2019
Final appraisal document - managed access agreement - TA592 (PDF 364 KB)

Published:

02 July 2019
Equality impact assessment - TA592 (PDF 144 KB)

Published:

07 August 2019
Register of interests - TA592 (PDF 169 KB)

Published:

08 August 2019

Invitation to participate

Final scope - TA592 (PDF 328 KB)

Published:

24 August 2018
Final stakeholder list - TA592 (PDF 259 KB)

Published:

21 January 2019
NICE's response to comments on the draft scope and provisional stakeholder list - TA592 (PDF 280 KB)

Published:

24 August 2018
Equality impact assessment (Scoping) - TA592 (PDF 120 KB)

Published:

24 August 2018